company background image
SIGA

SIGA Technologies NasdaqGM:SIGA Stock Report

Last Price

US$10.58

Market Cap

US$772.6m

7D

-2.6%

1Y

44.7%

Updated

28 Sep, 2022

Data

Company Financials +
SIGA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance6/6
Financial Health6/6
Dividends0/6

SIGA Stock Overview

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States.

SIGA Technologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SIGA Technologies
Historical stock prices
Current Share PriceUS$10.58
52 Week HighUS$26.99
52 Week LowUS$5.84
Beta0.67
1 Month Change-34.00%
3 Month Change-8.64%
1 Year Change44.73%
3 Year Change105.44%
5 Year Change225.54%
Change since IPO101.52%

Recent News & Updates

Sep 29

SIGA Technologies secures new contract awarded to procure up to $10.7M of TPOXX

SIGA Technologies (NASDAQ:SIGA) notifies that the U.S. Department of Defense awarded a new contract to SIGA for the procurement of up to $10.7M of oral TPOXX, of which $5.1M of oral TPOXX is targeted for delivery in 2022 and the remainder is subject to an option at the sole discretion of the DoD. The contract follows an award made earlier this year for the procurement of $7.4M of oral TPOXX, under which all product is expected to be delivered in 2022.    The project work is supported by a separate development contract worth ~$26M. Shares are up 3.12% premarket.

Sep 09

Siga monkeypox therapy undergoes NIH-led late-stage trial

On Friday, the National Institutes of Health (NIH) announced the start of a late-stage clinical trial to test Siga Technologies’ (NASDAQ:SIGA) Tpoxx antiviral pill on monkeypox patients. Tpoxx, approved in the U.S. for related smallpox infection, is also used to treat monkeypox on a case-by-case basis under the FDA's Expanded Access program. The NIH-led trial is expected to enroll 500 patients, both adults and children, who will be randomized to receive Tpoxx, also known as Tecovirimat, and the placebo. The study is designed to measure if Tpoxx recipients heal faster than those who receive the placebo and obtain critical data on optimal dosing and safety for children and pregnant women. Recently, a team of British scientists, who conducted one of the major clinical trials to find COVID-19 therapies, started a similar trial for Tpoxx in the U.K.

Aug 23

Scientists behind key COVID study run monkeypox trial for SIGA therapy

A team of British scientists, who conducted one of the major trials to find COVID-19 therapies, announced a new clinical study on Tuesday to evaluate whether the antiviral tecovirimat developed by SIGA Technologies (NASDAQ:SIGA) is effective against monkeypox. The scientists from Oxford University rose to fame in 2020 after initiating their so-called RECOVERY trial, which initially tested four treatments against COVID-19. Tecovirimat, also known as TPOXX, is currently available in the U.S. as a treatment for smallpox on a case-by-case basis under the FDA's Expanded Access program. The monkeypox trial named PLATINUM is funded by a ~$4.4M grant from the U.K. government. The randomized trial will enroll at least 500 participants who will receive a 14-day course of 600mg tecovirimat twice daily or a matched placebo. Previously, updating on its plans to launch global studies for TPOXX in monkeypox, SIGA (SIGA) said that the first trial sites in the U.K. would be activated this week.

Shareholder Returns

SIGAUS PharmaceuticalsUS Market
7D-2.6%3.7%-2.0%
1Y44.7%5.3%-20.3%

Return vs Industry: SIGA exceeded the US Pharmaceuticals industry which returned 4.2% over the past year.

Return vs Market: SIGA exceeded the US Market which returned -22.1% over the past year.

Price Volatility

Is SIGA's price volatile compared to industry and market?
SIGA volatility
SIGA Average Weekly Movement18.7%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: SIGA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: SIGA's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199539Phil Gomezhttps://www.siga.com

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.

SIGA Technologies Fundamentals Summary

How do SIGA Technologies's earnings and revenue compare to its market cap?
SIGA fundamental statistics
Market CapUS$772.60m
Earnings (TTM)US$71.77m
Revenue (TTM)US$147.41m

10.8x

P/E Ratio

5.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SIGA income statement (TTM)
RevenueUS$147.41m
Cost of RevenueUS$37.43m
Gross ProfitUS$109.98m
Other ExpensesUS$38.21m
EarningsUS$71.77m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.98
Gross Margin74.61%
Net Profit Margin48.69%
Debt/Equity Ratio0%

How did SIGA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SIGA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SIGA?

Other financial metrics that can be useful for relative valuation.

SIGA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.5x
Enterprise Value/EBITDA7.1x
PEG Ratio-0.5x

Price to Earnings Ratio vs Peers

How does SIGA's PE Ratio compare to its peers?

SIGA PE Ratio vs Peers
The above table shows the PE ratio for SIGA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average15.7x
TARO Taro Pharmaceutical Industries
12.6xn/aUS$1.1b
AVIR Atea Pharmaceuticals
31.1x47.2%US$482.1m
PAHC Phibro Animal Health
10.8x1.4%US$531.0m
INVA Innoviva
8.5xn/aUS$841.4m
SIGA SIGA Technologies
10.8x-22.2%US$772.6m

Price-To-Earnings vs Peers: SIGA is good value based on its Price-To-Earnings Ratio (10.8x) compared to the peer average (15.7x).


Price to Earnings Ratio vs Industry

How does SIGA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Earnings vs Industry: SIGA is good value based on its Price-To-Earnings Ratio (10.8x) compared to the US Pharmaceuticals industry average (12.6x)


Price to Earnings Ratio vs Fair Ratio

What is SIGA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SIGA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.8x
Fair PE Ratio18.8x

Price-To-Earnings vs Fair Ratio: SIGA is good value based on its Price-To-Earnings Ratio (10.8x) compared to the estimated Fair Price-To-Earnings Ratio (18.8x).


Share Price vs Fair Value

What is the Fair Price of SIGA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SIGA ($10.58) is trading below our estimate of fair value ($29.44)

Significantly Below Fair Value: SIGA is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is SIGA Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-22.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SIGA's earnings are forecast to decline over the next 3 years (-22.2% per year).

Earnings vs Market: SIGA's earnings are forecast to decline over the next 3 years (-22.2% per year).

High Growth Earnings: SIGA's earnings are forecast to decline over the next 3 years.

Revenue vs Market: SIGA's revenue is expected to decline over the next 3 years (-7.9% per year).

High Growth Revenue: SIGA's revenue is forecast to decline over the next 3 years (-7.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SIGA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has SIGA Technologies performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-6.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SIGA has high quality earnings.

Growing Profit Margin: SIGA's current net profit margins (48.7%) are higher than last year (45.8%).


Past Earnings Growth Analysis

Earnings Trend: SIGA has become profitable over the past 5 years, growing earnings by -6.1% per year.

Accelerating Growth: SIGA's earnings growth over the past year (64.2%) exceeds its 5-year average (-6.1% per year).

Earnings vs Industry: SIGA earnings growth over the past year (64.2%) exceeded the Pharmaceuticals industry 5%.


Return on Equity

High ROE: SIGA's Return on Equity (51.3%) is considered outstanding.


Discover strong past performing companies

Financial Health

How is SIGA Technologies's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: SIGA's short term assets ($153.6M) exceed its short term liabilities ($16.7M).

Long Term Liabilities: SIGA's short term assets ($153.6M) exceed its long term liabilities ($3.5M).


Debt to Equity History and Analysis

Debt Level: SIGA is debt free.

Reducing Debt: SIGA currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: SIGA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: SIGA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is SIGA Technologies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


4.25%

Forecast Dividend Yield

Dividend Yield vs Market

SIGA Technologies Dividend Yield vs Market
How does SIGA Technologies dividend yield compare to the market?
SegmentDividend Yield
Company (SIGA Technologies)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Pharmaceuticals)2.5%
Analyst forecast in 3 Years (SIGA Technologies)4.3%

Notable Dividend: Unable to evaluate SIGA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SIGA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SIGA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SIGA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SIGA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

11.6yrs

Average management tenure


CEO

Phil Gomez (55 yo)

5.75yrs

Tenure

US$1,688,264

Compensation

Dr. Phillip Louis Gomez III, also known as Phil, M.D., PhD, has been Chief Executive Officer of SIGA Technologies, Inc. since October 13, 2016 and has been its Director since December 6, 2016. Dr. Gomez wa...


CEO Compensation Analysis

Phil Gomez's Compensation vs SIGA Technologies Earnings
How has Phil Gomez's remuneration changed compared to SIGA Technologies's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

US$72m

Mar 31 2022n/an/a

US$70m

Dec 31 2021US$2mUS$844k

US$69m

Sep 30 2021n/an/a

US$16m

Jun 30 2021n/an/a

US$44m

Mar 31 2021n/an/a

US$64m

Dec 31 2020US$2mUS$820k

US$56m

Sep 30 2020n/an/a

US$32m

Jun 30 2020n/an/a

US$6m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$2mUS$796k

-US$7m

Sep 30 2019n/an/a

US$50m

Jun 30 2019n/an/a

US$439m

Mar 31 2019n/an/a

US$435m

Dec 31 2018US$2mUS$773k

US$422m

Sep 30 2018n/an/a

US$359m

Jun 30 2018n/an/a

-US$39m

Mar 31 2018n/an/a

-US$39m

Dec 31 2017US$2mUS$750k

-US$36m

Sep 30 2017n/an/a

-US$36m

Jun 30 2017n/an/a

-US$36m

Mar 31 2017n/an/a

-US$38m

Dec 31 2016US$2mUS$163k

-US$40m

Compensation vs Market: Phil's total compensation ($USD1.69M) is below average for companies of similar size in the US market ($USD4.14M).

Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SIGA's management team is seasoned and experienced (11.6 years average tenure).


Board Members

Experienced Board: SIGA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGM:SIGA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Dec 21SellUS$234,600James AntalIndividual30,000US$7.82

Ownership Breakdown

What is the ownership structure of SIGA?
Owner TypeNumber of SharesOwnership Percentage
General Public8,726,65912.0%
Individual Insiders9,447,20312.9%
VC/PE Firms24,156,35833.1%
Institutions30,693,92742.0%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 77.07% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
33.08%
MacAndrews & Forbes Incorporated
24,156,358$255.6m0%46.31%
6.82%
John Lewis
4,982,719$52.7m0%no data
4.68%
BlackRock, Inc.
3,419,333$36.2m-4.7%no data
4.4%
D. E. Shaw & Co., L.P.
3,216,528$34.0m2130.51%0.06%
4.05%
Esopus Creek Advisors Llc
2,954,692$31.3m0%99.96%
2.96%
The Vanguard Group, Inc.
2,159,386$22.8m-3.36%no data
2.55%
AltraVue Capital, LLC
1,862,476$19.7m-24.66%2.73%
2.04%
Paul Saunders
1,489,344$15.8m0%no data
2%
Kempen Capital Management N.V.
1,461,871$15.5m6.16%0.3%
1.56%
Dimensional Fund Advisors LP
1,138,032$12.0m19.46%no data
1.46%
Eric Rose
1,068,593$11.3m0%no data
1.36%
State Street Global Advisors, Inc.
992,844$10.5m-6.71%no data
1.21%
Hutch Capital Management LLC
880,100$9.3m0%no data
1.2%
Marshall Wace LLP
878,129$9.3m0%0.02%
1.1%
MFP Investors LLC
804,559$8.5m-29.95%1.51%
1.08%
Geode Capital Management, LLC
785,974$8.3m-3.44%no data
0.92%
Two Sigma Investments, LP
668,204$7.1m0%0.03%
0.87%
Renaissance Technologies LLC
637,511$6.7m-6.98%0.01%
0.65%
Phillip Gomez
475,782$5.0m0%no data
0.61%
Northern Trust Global Investments
447,588$4.7m2.67%no data
0.56%
Legato Capital Management, LLC
409,310$4.3m-24.48%1.02%
0.56%
Voloridge Investment Management, LLC
405,756$4.3m0%0.02%
0.45%
New York State Common Retirement Fund
331,186$3.5m-22.99%no data
0.45%
Thomas Constance
327,806$3.5m0%no data
0.45%
Point72 Asset Management, L.P.
326,640$3.5m0%0.01%

Company Information

SIGA Technologies, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: SIGA Technologies, Inc.
  • Ticker: SIGA
  • Exchange: NasdaqGM
  • Founded: 1995
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$772.595m
  • Shares outstanding: 73.02m
  • Website: https://www.siga.com

Number of Employees


Location

  • SIGA Technologies, Inc.
  • 31 East 62nd Street
  • New York
  • New York
  • 10065
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SIGANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDSep 1997

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.